SO
CRNX icon

STRS Ohio’s Crinetics Pharmaceuticals CRNX Stock Holding History

STRS Ohio’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Sell
3,500
-1,800
-34% -$80.4K ﹤0.01% 1692
2025
Q4 		$247K Buy
5,300
+4,100
+342% +$183K ﹤0.01% 1425
2025
Q3 		$50K Sell
1,200
-500
-29% -$16K ﹤0.01% 2004
2025
Q2 		$48.9K Sell
1,700
-2,000
-54% -$61.8K ﹤0.01% 2029
2025
Q1 		$124K Sell
3,700
-3,200
-46% -$120K ﹤0.01% 1622
2024
Q4 		$353K Buy
6,900
+2,200
+47% +$123K ﹤0.01% 1328
2024
Q3 		$240K Sell
4,700
-2,400
-34% -$124K ﹤0.01% 1512
2024
Q2 		$318K Buy
7,100
+6,700
+1,675% +$309K ﹤0.01% 1424
2024
Q1 		$18K Buy
+400
New +$15.7K ﹤0.01% 1859
2019
Q1 		– Sell
-2,000
Closed -$59K – 2057
2018
Q4 		$59K Hold
2,000
– – ﹤0.01% 1850
2018
Q3 		$57K Buy
+2,000
New +$59.4K ﹤0.01% 1928

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

STRS Ohio's CRNX Position: Q1 2026 in Review

STRS Ohio reduced its Crinetics Pharmaceuticals (CRNX) stake by 34% in Q1 2026, selling an estimated $80.4K and leaving 3,500 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1692.

STRS Ohio first reported a position in CRNX in Q3 2018 and has held it in 11 quarters since. The position peaked at $353K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • STRS Ohio held 3,500 shares of Crinetics Pharmaceuticals worth $127K as of Q1 2026.
  • STRS Ohio sold 1,800 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $80.4K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of STRS Ohio's portfolio in Q1 2026, its #1692 holding.
  • STRS Ohio first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 11 quarters since.
  • STRS Ohio's Crinetics Pharmaceuticals position peaked at $353K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.